Zacks: Brokerages Expect MOTIF BIO PLC/S (MTFB) to Post -$0.45 Earnings Per Share

Equities analysts predict that MOTIF BIO PLC/S (NASDAQ:MTFB) will announce earnings of ($0.45) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for MOTIF BIO PLC/S’s earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.31). The firm is expected to issue its next quarterly earnings report on Tuesday, April 9th.

According to Zacks, analysts expect that MOTIF BIO PLC/S will report full year earnings of ($2.13) per share for the current fiscal year, with EPS estimates ranging from ($2.85) to ($1.15). For the next year, analysts anticipate that the business will post earnings of ($1.14) per share, with EPS estimates ranging from ($2.15) to ($0.48). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for MOTIF BIO PLC/S.

A number of brokerages have recently commented on MTFB. HC Wainwright set a $32.00 target price on shares of MOTIF BIO PLC/S and gave the stock a “buy” rating in a research report on Tuesday, October 9th. ValuEngine lowered shares of MOTIF BIO PLC/S from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd.

Shares of NASDAQ:MTFB opened at $9.86 on Monday. The company has a market cap of $114.21 million, a PE ratio of -51.89 and a beta of 0.74. MOTIF BIO PLC/S has a one year low of $4.42 and a one year high of $11.50.

About MOTIF BIO PLC/S

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

Read More: What are municipal bonds?

Get a free copy of the Zacks research report on MOTIF BIO PLC/S (MTFB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply